Wilmington Savings Fund Society FSB Sells 75,143 Shares of Pfizer Inc. $PFE

Wilmington Savings Fund Society FSB lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 25.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 215,728 shares of the biopharmaceutical company’s stock after selling 75,143 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Pfizer were worth $5,497,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of PFE. Norges Bank bought a new position in shares of Pfizer during the 2nd quarter worth about $2,270,157,000. Franklin Resources Inc. increased its stake in Pfizer by 47.8% during the third quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock valued at $638,787,000 after acquiring an additional 8,108,887 shares during the period. Neuberger Berman Group LLC lifted its position in shares of Pfizer by 203.8% in the 3rd quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company’s stock worth $229,346,000 after acquiring an additional 6,045,763 shares during the period. Ameriprise Financial Inc. grew its holdings in shares of Pfizer by 48.2% during the 3rd quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock worth $468,174,000 after purchasing an additional 5,978,927 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its position in Pfizer by 43.4% in the second quarter. Arrowstreet Capital Limited Partnership now owns 18,718,955 shares of the biopharmaceutical company’s stock worth $453,747,000 after purchasing an additional 5,662,309 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on PFE. Barclays started coverage on shares of Pfizer in a research report on Thursday, February 19th. They set an “underweight” rating and a $25.00 target price on the stock. TD Cowen reiterated a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Finally, HSBC raised their price objective on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and an average target price of $28.14.

Pfizer Stock Down 0.5%

NYSE:PFE opened at $27.33 on Thursday. The stock’s fifty day moving average price is $26.61 and its two-hundred day moving average price is $25.57. The company has a market cap of $155.38 billion, a price-to-earnings ratio of 20.09 and a beta of 0.47. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.94. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company’s revenue was down 1.2% on a year-over-year basis. During the same period last year, the company earned $0.63 earnings per share. On average, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase 3 topline — Pfizer reported positive topline results from the Phase 3 TALAPRO-3 study showing TALZENNA (talazoparib) plus XTANDI (enzalutamide) significantly improved radiographic progression‑free survival in HRR‑mutated metastatic castration‑sensitive prostate cancer, a meaningful late‑stage win that could expand a high‑value oncology franchise. TALAPRO-3 Topline
• Positive Sentiment: Mid‑stage breast cancer data supports pipeline — Pfizer’s Phase 2 FOURLIGHT‑1 trial of atirmociclib met its primary endpoint in second‑line HR+/HER2‑ metastatic breast cancer, cutting risk of progression and strengthening Pfizer’s bid to follow on from CDK4/6 leaders (Ibrance, etc.). This readout is being positioned as a key oncology catalyst. Atirmociclib Phase 2 Results
• Positive Sentiment: Analyst upgrade and price‑target lift — HSBC raised its price target to $32 and moved to a buy rating, citing upside to Pfizer’s valuation; that upgrade has drawn investor attention and provided near‑term support. HSBC Upgrade
• Neutral Sentiment: Early‑stage liver program advanced — Pfizer updated progress on a Phase 1 PF‑07328948 liver study, which modestly supports the pipeline but is an early, lower‑visibility catalyst. PF‑07328948 Liver Study
• Neutral Sentiment: Public commentary and investor interest — Media/columnist coverage (including Jim Cramer) and various valuation pieces have increased attention on PFE, driving trading volume but not a clear directional catalyst. Cramer & Media Coverage
• Negative Sentiment: Program trimming: early‑stage melanoma study ended — Pfizer discontinued an early‑stage melanoma study (PF‑08046031), which trims one oncology bet and tempers the otherwise bullish pipeline narrative. Melanoma Study Stop
• Negative Sentiment: Industry pricing scrutiny — A Reuters/analysis piece on TrumpRx highlights continued political scrutiny of U.S. drug prices; broader policy and pricing headlines can pressure large pharma multiples and investor sentiment for companies like Pfizer. TrumpRx Pricing Analysis

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.